Cancer Molecular Imaging

癌症分子影像计划区由18名成员组成，跨越7个部门， 加州大学洛杉矶分校在过去的竞争周期中，该计划的研究人员撰写了265篇出版物，其中232篇 (88 89项（34%）为方案间，89项（34%）为方案内。71人（27%）被安置在高影响力 ournals。该计划领域的9个成员使用了目前资助的8个共享资源中的6个 的JCCC。在本资助年度，同行评审的资金总额为440万美元， 其中包括来自国家癌症研究所的380万美元。与其他计划领域一样，JCCC促进了 许多互动活动和许多共享资源支持CMI中的研究者 程序区。在目前的赠款周期内，来自JCCC的资金以CCSG发展的形式提供， 基金，机构支持和慈善捐赠给CMI计划领域共计317，584美元。这些资金 支持种子赠款、招聘/保留和计划领域领导支持。四是方案领域 成员是JCCC支持的受益者。 分子成像是一套强大的方法，可以揭示活体的功能变化， 使人们对人类健康和疾病有了令人信服的见解。新提出的JCCC癌症分子 成像程序区汇集了共同关注采用分子成像的研究人员 研究活体癌症的工具，从实验室啮齿动物模型到患者。CMI的努力 调查人员围绕四个主题进行组织。1)仪器和分析的发展 工具.分子成像的发展需要仪器的不断发展和改进 为生物分子和过程提供更高的分辨率、灵敏度和定量测量 in vivo. 2)新型分子影像学方法的发展。CMI计划区成员已 分子成像领域的领导者，在新型示踪剂、成像基因 使用报告基因表达，开发动物模型以利用非侵入性的优势， 重复和定量成像，并在多模态成像仪器和分析的发展 程序.这些工具用于研究癌症的发生和进展、转移性扩散， 在临床前模型中对治疗的反应。3)成像免疫反应和对 免疫疗法CMI计划领域的一个重要重点是开发监测免疫的工具， 反应，并遵循癌症免疫疗法在活体个体中的效果。4)影像翻译 技术应用于癌症患者的临床环境。最终，CMI计划领域的目标是 提高对癌症的理解、检测和治疗。CMI计划区成员追求 翻译目标，包括确定目前可用的分子示踪剂的最佳使用， 诊所（例如，FDG-PET、FLT-PET）以及通过临床评价翻译新的分子示踪剂。

The Cancer Molecular Imaging Program Area is composed of 18 members, spanning 7 Departments within UCLA. In the past competing cycle, investigators from this Program authored 265 publications, of which 232 (88%) were inter-programmatic and 89 (34%) intra-programmatic. 71 (27%) were placed in high-impact ournals. Nine members of this Program Area used 6 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $4.4 million in total costs, including $3.8 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CMI Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CMI Program Area total $317,584. These funds supported Seed Grants, recruitment/retention & Program Area Leadership support. Four of the Program Area Members were the recipients of JCCC support. Molecular imaging is a powerful set of approaches to reveal functional changes in living subjects that has enabled compelling insights into human health and disease. The newly proposed JCCC Cancer Molecular Imaging Program Area brings together investigators with a common focus on employing molecular imaging tools to investigate cancer in living individuals, from laboratory rodent models to patients. The efforts of CMI investigators are organized around four main themes. 1) Development of instrumentation and analytical tools. Moving molecular imaging forward requires constant development and improvement in instrumentation to provide higher resolution, sensitivity, and quantitative measurement of biological molecules and processes in vivo. 2) Development of novel molecular imaging approaches. CMI Program Area members have been leaders in the field of molecular imaging, with significant contributions in novel tracers, imaging gene expression using reporter genes, developing animal models to exploit the advantages of non-invasive, repeated and quantitative imaging, and in development of multimodality imaging instrumentation and analytic procedures. These tools are employed in the study of cancer initiation and progression, metastatic spread, and response to treatment, in preclinical models. 3) Imaging immune responses and response to immunotherapy. An important focus of the CMI Program Area is to develop the tools to monitor immune responses and follow the effects of cancer immunotherapy in living individuals. 4) Translation of imaging technologies to clinical contexts for cancer patients. Ultimately, the goal of the CMI Program Area is to improve the understanding, detection, and treatment of cancer. CMI Program Area members pursue translational goals that include both determining the best use of currently available molecular tracers in the clinic (e.g., FDG-PET, FLT-PET) as well as translating new molecular tracers through clinical evaluation.